LT3675826T - Katijoninės lipidų kompozicijos audiniams-specifiniam įterpimui - Google Patents
Katijoninės lipidų kompozicijos audiniams-specifiniam įterpimuiInfo
- Publication number
- LT3675826T LT3675826T LTEPPCT/US2018/042555T LTUS2018042555T LT3675826T LT 3675826 T LT3675826 T LT 3675826T LT US2018042555 T LTUS2018042555 T LT US2018042555T LT 3675826 T LT3675826 T LT 3675826T
- Authority
- LT
- Lithuania
- Prior art keywords
- tissue
- cationic lipid
- specific delivery
- lipid compositions
- compositions
- Prior art date
Links
- -1 Cationic lipid Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762552783P | 2017-08-31 | 2017-08-31 | |
PCT/US2018/042555 WO2019045897A1 (en) | 2017-08-31 | 2018-07-17 | CATIONIC LIPIDIC COMPOSITIONS FOR TISSUE-SPECIFIC ADMINISTRATION |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3675826T true LT3675826T (lt) | 2023-09-11 |
Family
ID=63104088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEPPCT/US2018/042555T LT3675826T (lt) | 2017-08-31 | 2018-07-17 | Katijoninės lipidų kompozicijos audiniams-specifiniam įterpimui |
Country Status (8)
Country | Link |
---|---|
US (2) | US20190060482A1 (lt) |
EP (1) | EP3675826B1 (lt) |
JP (2) | JP7379325B2 (lt) |
CN (1) | CN111065377A (lt) |
AU (1) | AU2018324345A1 (lt) |
CA (1) | CA3073851A1 (lt) |
LT (1) | LT3675826T (lt) |
WO (1) | WO2019045897A1 (lt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11690921B2 (en) * | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
KR20210153077A (ko) | 2019-04-16 | 2021-12-16 | 장피트 | 마이크로-rna 의 안정화를 위한 조성물 및 방법 |
AU2020301036A1 (en) * | 2019-07-03 | 2022-02-17 | Factor Bioscience Inc. | Cationic lipids and uses thereof |
US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
EP3865122A1 (en) * | 2020-02-11 | 2021-08-18 | Pantherna Therapeutics GmbH | Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium |
WO2024006937A1 (en) * | 2022-06-30 | 2024-01-04 | Life Technologies Corporation | Lipid compositions for in vivo delivery |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
ATE383331T1 (de) | 1998-11-12 | 2008-01-15 | Invitrogen Corp | Transportreagentien |
CA2785492C (en) | 2009-12-23 | 2018-07-24 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
EP2640700B1 (en) * | 2010-11-15 | 2018-10-31 | Life Technologies Corporation | Amine-containing transfection reagents and methods for making and using same |
CN106572974B (zh) * | 2014-07-15 | 2021-04-23 | 生命技术公司 | 用于将分子有效递送到细胞的具有脂质聚集体的组合物和方法 |
CN107849567A (zh) * | 2015-06-26 | 2018-03-27 | 苏州瑞博生物技术有限公司 | 一种siRNA、含有该siRNA的药物组合物和缀合物及它们的应用 |
-
2018
- 2018-07-17 EP EP18749995.9A patent/EP3675826B1/en active Active
- 2018-07-17 CA CA3073851A patent/CA3073851A1/en active Pending
- 2018-07-17 CN CN201880056879.8A patent/CN111065377A/zh active Pending
- 2018-07-17 AU AU2018324345A patent/AU2018324345A1/en active Pending
- 2018-07-17 WO PCT/US2018/042555 patent/WO2019045897A1/en unknown
- 2018-07-17 LT LTEPPCT/US2018/042555T patent/LT3675826T/lt unknown
- 2018-07-17 US US16/038,107 patent/US20190060482A1/en not_active Abandoned
- 2018-07-17 JP JP2020512589A patent/JP7379325B2/ja active Active
-
2021
- 2021-07-16 US US17/378,466 patent/US20220001023A1/en active Pending
-
2023
- 2023-07-14 JP JP2023115742A patent/JP2023138526A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3073851A1 (en) | 2019-03-07 |
EP3675826B1 (en) | 2023-05-31 |
JP7379325B2 (ja) | 2023-11-14 |
JP2020532546A (ja) | 2020-11-12 |
US20220001023A1 (en) | 2022-01-06 |
AU2018324345A1 (en) | 2020-03-05 |
US20190060482A1 (en) | 2019-02-28 |
WO2019045897A1 (en) | 2019-03-07 |
CN111065377A (zh) | 2020-04-24 |
EP3675826A1 (en) | 2020-07-08 |
JP2023138526A (ja) | 2023-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL290592A (en) | A cationic lipid that can be ionized for the administration of RNA | |
HK1244479A1 (zh) | 用於rna遞送的可電離陽離子脂質 | |
HK1245071A1 (zh) | 用於回腸-空腸給藥的組合物 | |
LT3675826T (lt) | Katijoninės lipidų kompozicijos audiniams-specifiniam įterpimui | |
EP3368084A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR TRANSMUCOSAL RELEASE | |
ZA201707475B (en) | Compositions comprising antibody-duocarmycin drug conjugates | |
IL262574B (en) | cationic lipid | |
IL263838A (en) | Phospholipid compounds | |
IL280620A (en) | cationic fat | |
IL255275A0 (en) | Preparations containing enquinara | |
SG11201704137RA (en) | Formulation for effective tocotrienol delivery | |
HK1254769A1 (zh) | 包含s1p受體調節劑的組合物 | |
GB201514902D0 (en) | Formulations for transmucosal delivery | |
HK1244184A1 (zh) | 用於改善睡眠的脂質組合物 | |
GB201702546D0 (en) | Oral delivery compositions | |
GB201514906D0 (en) | Formulations for transmucosal delivery |